Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of CoLucid Pharmaceuticals Inc (NASDAQ: CLCD) acted responsibly on behalf of investors’ profitability in the planned $960 million sale to Eli Lilly and Company (NYSE: LLY).

On January 18, 2017, CoLucid Pharmaceuticals Inc (NASDAQ: CLCD) and Eli Lilly and Company (NYSE: LLY) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Eli Lilly will offer CoLucid shareholders $46.50 per share in cash for all outstanding shares.    

Based in Cambridge, Massachusetts, and founded in 2005 CoLucid Pharmaceuticals Inc a biopharmaceutical company, develops small molecules for the acute treatment of migraine.

The investigation is looking to uncover whether CoLucid Pharmaceuticals Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $52.00 per share.

If you purchased CoLucid Pharmaceuticals Inc (NASDAQ: CLCD) prior to January 18, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185